Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 181-192

  Redhage, Leigh Anne ^a   Shintani, Ayumi ^b   Haas, David W ^b   Emeagwali, Nkiruka ^c   Markovic, Milica ^d   Oboho, Ikwo ^e   Mwenya, Christopher ^b   Erdem, Husamettin ^b   Acosta, Edward P ^f   Morrow, Jason D ^b   Hulgan, Todd ^a,b,g  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d Department of Anesthesia   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g Center for Health Services Research ^*  (United States)

Author keywords

Antiretroviral therapy; F2 isoprostanes; Highly active; HIV; Lipid peroxidation; Oxidative stress

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CHOLESTEROL; EFAVIRENZ; INDINAVIR; ISOPROSTANE DERIVATIVE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG USE; ETHNICITY; FATTY ACID BLOOD LEVEL; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL MODEL;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; F2-ISOPROSTANES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX FACTORS; TENNESSEE; YOUNG ADULT; ZIDOVUDINE;

EID: 69249131696     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-181     Document Type: Article

References (45)

1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefi ts of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11-19.
2. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296(7):844-854.
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside analogue reversetranscriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112-1115.
4. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest. 2001;81(11): 1537-1544.
5. Day L, Shikuma C, Gerschenson M. Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. Mitochondrion. 2004;4 (2-3):95-109.
6. Olinski R, Gackowski D, Foksinski M, Rozalski R, Roszkowski K, Jaruga P. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodefi ciency syndrome. Free Radic Biol Med. 2002;33(2): 192-200.
7. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723- 1735.
8. Day BJ, Lewis W. Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo. Cardiovasc Toxicol. 2004;4(3): 207-216.
9. Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004;128(1-2):117-124.
10. Shishehbor MH, Zhang R, Medina H, et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med. 2006;41(11):1678-1683.
11. Gil L, Perez D, Tapanes R, Perez J, Grune T. Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a benefi cial option? Redox Rep. 2005;10(3):113-119.
12. Dobmeyer TS, Findhammer S, Dobmeyer JM, et al. Ex vivo induction of apoptosis in lymphocytes is mediated by oxidative stress: role for lymphocyte loss in HIV infection. Free Radic Biol Med. 1997;22(5):775-785.
13. Valcour V, Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion. 2004;4(2-3):119-129.
14. Stehbens WE. Oxidative stress in viral hepatitis and AIDS. Exp Mol Pathol. 2004;77(2):121-132.
15. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res. 2000;47(3):410-418.
16. Jaruga P, Jaruga B, Gackowski D, et al. Supplementation with antioxidant vitamins prevents oxidative modifi cation of DNA in lymphocytes of HIV-infected patients. Free Radic Biol Med. 2002;32(5):414-420.
17. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36(1):1-21.
18. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332(18):1198-1203.
19. Stein CM, Tanner SB, Awad JA, Roberts LJ II, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39(7):1146-1150.
20. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ II. Cerebrospinal fl uid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998;44(3):410-413.
21. Konishi M, Iwasa M, Araki J, et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8- isoprostane. J Gastroenterol Hepatol. 2006;21(12):1821-1825.
22. Ikizler TA, Morrow JD, Roberts LJ, et al. Plasma F2- isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58(3):190-197.
23. McComsey GA, Morrow JD. Lipid oxidative markers are signifi cantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr. 2003;34(1):45-49.
24. Hulgan T, Morrow J, D'Aquila RT, et al. Oxidant stress is increased during treatment of human immunodefi ciency virus infection. Clin Infect Dis. 2003;37(12):1711-1717.
25. Morrow JD, Roberts LJ II. Mass spectrometric quantifi cation of F2-isoprostanes as indicators of oxidant stress. Methods Mol Biol. 2002;186:57-66.
26. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784(2):331-341.
27. Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag; 2001.
28. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434-439.
29. Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002;156(3):274-285.
30. Gross M, Steffes M, Jacobs DR Jr, et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem. 2005;51(1):125-131.
31. Ide T, Tsutsui H, Ohashi N, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol. 2002;22(3):438-442.
32. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000;14(7):807-812.
33. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodefi - ciency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003;88(11):5186-5192.
34. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16(10):1383-1389.
35. Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest. 2004;34(8):569-575.
36. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapinebased therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20(6):589-594.
37. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTIbased therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10(5):585-591.
38. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine- containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profi le. AIDS. 2001;15(18):2407-2414.
39. Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45(2):263-266.
40. Clotet B, van der Valk M, Negredo E, Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S79-84.
41. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):e19.
42. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profi les. AIDS Patient Care STDS. 2006;20(8):542-548.
43. Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr. 2005;38(2):236-238.
44. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279(15):15130-15141.
45. Hulgan T, Hughes M, Sun X, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr. 2006;42(4):450-454.